AMEA
The most clinically validated liquid biopsy is
10x bigger with exceptional sensitivity.1,2
Coverage of 730+ genes
with variants detected
as low as 0.001% MAF1
Important note: Guardant360 was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.
Accurately quantify disease burden with methylation-based
tumor fraction3,4
Broad coverage
with >92% of patients
paying $0†
MAF, mutant allele fraction.
*Median turnaround time from sample receipt to results.
†More than 92% of patients are assigned $0 by their insurance for a Guardant360 test.
Fast results
in 7 days5*